Intelligence · M&A & Funding
Every cannabis deal — and the companies behind them.
Free — what your email unlocks
The full tracker. Every deal. No paywall on the data.
What the data shows
2026 is running a third ahead of the record year.
Three phases: the 2021 legalisation spike (75), a two-year retreat, then a rebuild that has now run three straight years. 2026 passed 100 deals on 11 August — 31% ahead of the same date in 2025, and 2025 was itself the busiest full year on record at 132.
2026 shown year-to-date (gold). Two records carry no date and are excluded.
The US and Canada carry more than half of all country tags — but Germany, at 84, is the largest market outside North America, ahead of the UK at 60. The top four markets account for roughly 76% of every tag in the record.
A deal can be tagged to more than one market, so tags exceed deals.
Just over half of typed deals are acquisitions. Financing is the other engine — 119 equity raises and 51 debt raises, 170 between them. And 462 of 597 deals have actually closed — the rest are live, or, in 19 cases, collapsed and kept on the record.
46 records carry no deal type yet and are omitted from the upper chart.
Manufacturing and cultivation remain the most-tagged layers, but retail and distribution together (318) now outweigh either of them. Buyers are paying for the route to the patient, not only for the plant.
Segments overlap — one deal can touch several layers.
Medical is tagged on 333 deals against recreational's 224 — the record leans medical, which is where the European and Australian markets sit.
Verticals overlap: figures are deals tagged, not shares of 100%.
Ten companies account for 112 appearances across the record. Curaleaf leads at 16 — and on 11 August 2026 tabled a proposed take-over of Aurora, itself at 10. Inside Decide each name opens its full company profile.
Counts appearances on either side of a deal, not acquisitions made.
All 600+ deals, every field, filters and source links — normalised to USD and source-linked. Just your email. No credit card.
Form not loading? Open it in a new tab →
You can find most cannabis deals. You just can't reliably compare them.
Cannabis deal news is everywhere; comparable deal data is not. So the simple questions stay unanswerable. Five things stop news from being usable data — here's how the Cannamonitor Deal Tracker fixes each.
Each problem, and the fix. Tap to expand ↓
Methodology · the trust layer
How we build it.
Landmark deals · and one live proposal
The deals that shaped the industry.
Proposed take-over · 45% premium to 30-day VWAP. The record carries proposals, not only completions — which is why a transaction two days old is already on the same schema as a deal from 2018.
Yes. Your email unlocks the full deal record — all deals, filters and source links. Paid tiers only add ongoing monitoring (Essentials) and company depth (Decide).
A model can summarise news; it can’t give you 600+ deals normalised to one currency basis with the source filing attached. The Tracker is a structured database, not a summary.
News tells you a deal happened; the Tracker tells you the consideration, structure and multiple — and how it compares to every other deal on the same schema.
They stay on the record, marked withdrawn — 19 of them today. A database that quietly deletes collapsed deals tells you a rosier story than the market actually had.
The live tracker updates continuously; this page is stamped with its extract date (13 Aug 2026). Inside Decide, the tracker updates in real time.
Every figure links to its source. Disclosed-only fields are never estimated silently — if a value wasn’t public, it’s logged as undisclosed, not guessed.
Go deeper
Got the deals. Here’s what staying — and going deeper — buys.
Got the deals — now stay on top of them. Essentials adds an ongoing news stream, a monthly recap of M&A deals across 30+ markets, and insight deep-dives on the specific deals that matter.
The tracker shows transactions. Decide connects each deal to the company behind it — so you can underwrite what the deal actually means:
- Earnings & financials — revenue, EBITDA and margins over time
- Company news — every development, matched to the company
- Clinical trials — pipeline, matched by company
- Landscape deep dives — how the deal reshapes the map
Compare plans